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Proprotein convertase subtilisin/kexin 9 (PCSK9) is a notable target for the treatment of hypercholesterolemia 
because it regulates the population of the low-density lipoprotein receptor (LDLR) on liver cells. The PCSK9 
zymogen is a serine protease that spontaneously undergoes a double self-cleavage step. The available X-ray 
structures depict the PCSK9 mature state, but the atomic details of the zymogen state of the enzyme are still 
unknown. Additionally, why the protease activity of PCSK9 is blocked after the second autoprocessing step 
remains unclear, as this deviates from other members of the PCSK family. By performing constant-pH molecular 
dynamics (MD) simulations, we investigated the protonation state of the catalytic triad of PCSK9 and found that 
it strongly influences the catalytic properties of the enzyme. Moreover, we determined the final step of the 
maturation process by classical and steered MD simulations. This study could facilitate the identification of ligands 






  Proprotein convertase subtilisin/kexin 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-c) 
levels by direct interaction with the LDL receptor (LDLR).[1] Their protein–protein interaction (PPI) on the surface 
of the hepatocytes directs the LDLR to degradation via the lysosome pathway. As a consequence, the physiological 
activity of PCSK9 leads to an increment in the circulating cholesterol levels by decreasing the LDLR population 
on liver cell membranes. For this reason, PCSK9 inhibition represents a valuable therapeutic strategy for the 
treatment of hypercholesterolemia and consequent coronary heart disease.[2,3] Evolocumab[4] and alirocumab[5], 
two monoclonal antibodies (mAbs) endowed with PCSK9 inhibitory activity, have been released on the market to 
treat statin-resistant hypercholesterolemia. However, this type of therapy is characterized by high cost and low 
patient compliance; therefore, both industry and academic research activities are focused on the development of 
alternative therapeutic strategies like the usage of small molecules,[6] peptides,[7-11] or peptidomimetics[12,13] capable 
of impairing the PCSK9/LDLR PPI. Additionally, another promising strategy to decrease the circulating level of 
PCSK9 is inhibition of PCSK9 synthesis by means of small interfering RNA, such as inclisiran,[14] or the use of 
small molecules capable of blocking the maturation process of the enzyme. PCSK9 is a 72-kDa zymogen 
comprised of 692 amino acids, which are synthesized in the endoplasmic reticulum as a glycoprotein and are 
unable to bind to LDLR. The PCSK9 zymogen is constituted by a signal sequence (residues 1–30), an N-terminal 
domain (prodomain, residues 31–152), a catalytic domain (residues 153–425), and a C-terminal (or V) domain 
(residues 426–692) (Figure 1).[15] By the hydrolysis of the signal peptide (first autocatalytic step), the zymogen is 
converted into proPCSK9. Then, by a second autoprocessing step in which the amide bond between Gln152 and 
Ser153 is hydrolyzed, the proPCSK9 is converted into its mature state (PCSK9) and is secreted outside the liver 
cells.[16] Considering its zymogenic nature and the competitive inhibition of its catalytic activity by small 
molecules, the consequent impairment of the maturation process represents one possible drug design strategy. In 
2016, Salowe et al.[17] reported a biochemical method for the discovery of covalent autocleavage inhibitors, 
describing the kinetic properties of a lactone tool compound. To the best of our knowledge, no other irreversible 
inhibitors of PCSK9 have been reported in the literature. Thus, in order to design new compounds, insights into 
the autoprocessing mechanism are still needed. In light of these results, new strategies to target PCSK9 should be 
identified.   
   The available X-ray structures depict PCSK9 (Figure 1, residues 61–692) in the mature state, but no structural 
information about the other states is available. Curiously, all the available X-ray structures display the prodomain 
still bound to the catalytic domain and to the prodomain C-terminal end (Gln152) at a distance of about 20 Å from 
the catalytic domain N-term (Ser153). Both are spaced out by a hairpin created by residues 366–383. Since Gln152 
and Ser153 are covalently bound in the proPCSK9 state, a huge conformational modification of the enzyme could 
be expected throughout the second maturation step. Moreover, unlike other enzymes belonging to the same family 
of subtilisin/kexin proteins, the protease activity of PCSK9 is interrupted after the second phase of self-catalysis. 
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This avoids a third autocatalytic cleavage and protects the surrounding proteins from the protease activity of 
PCSK9. However, while this last aspect could be explained by the fact that the prodomain occupies the catalytic 
site, preventing access to other proteins, it is unclear why a third step of hydrolysis does not occur.[18]  
 
 
Figure 1. Graphical representation of the proPCSK9 model and hydrolysis reaction performed by the proPCSK9 
zymogen.[19]  
 
   Therefore, we report on computational studies aimed at predicting the conformational modifications of PCSK9 
after the second auto-maturation process, providing mechanistic insights into the Ser153 N-term removal from the 
catalytic site. Additionally, constant-pH molecular dynamics (CpHMD) simulations were performed because we 
predict that a change in the protonation state of the charged amino acids located in the PCSK9 catalytic site could 
affect the progression of the self-proteolysis process. Our computational results could suggest strategies to design 
new PCSK9 inhibitors using an approach that does not target the PCSK9/LDLR PPI.[7-9,12] 
COMPUTATIONAL METHODS 
ProPCSK9 models setup. The low-resolution X-ray structures disclose atomistic details of PCSK9 from residue 
61 to 682.[11,20,21] These studies revealed the conformation of PCSK9 in the mature state, in which the prodomain 
was already cleaved from the catalytic domain, and the Ser153 N-terminus was a distance of about 20 Å from the 
Gln152 C-terminus. Furthermore, the presence of highly flexible loops in the PCSK9 sequence led to incomplete 
X-ray structures (i.e., sequence 173–178 has not been solved). Therefore, the Modeller9.21 algorithm[22] was 
employed, and the human PCSK9 sequence stored in the UniProt database with code Q8NBP7 and the PCSK9 X-
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ray crystal structure stored in Protein Data Bank with code 2P4E[20] were used as templates to build a reliable and 
complete proPCSK9 model. In this model (named proPCSK9), the Gln152 and Ser153 were still bound by the 
amide bond, representing a model of the immature state of the enzyme. One hundred models were produced by 
Modeler9.21[22] and scored by the atomic distant-dependent potential known as discrete optimized protein energy 
(DOPE).[23] The best quality model attained from Modeler was geometrically optimized and equilibrated by 750 
ns of MD simulations using Amber19[24] following the protocols described in our previous works.[8,9] Moreover, 
in order to gain insights into the biochemical process occurring immediately before the catalytic cleavage of 
proPCSK9, an additional model (named proPCSK9-cut) was created. This model, in which Gln152-Ser153 had 
just been cleaved using the molecular modeling tools available on the Maestro software,[25] was used to predict the 
PCSK9 conformational modifications occurring immediately after the second self-cleavage step. In other words, 
energy minimization and MD simulations in the proPCSK9-cut model allowed us to determine the enzyme 
maturation process. This model also served to predict the pKa values of the amino acids that play a critical role in 
the catalytic site.  
Steered MD simulations. Steered MD (SMD) simulations[26] are a well-validated tool in structure-based drug 
design. They can provide the atomistic description and potential of mean force (PMF) profile of the simulated 
process (i.e., the channel opening and ligand unbinding process). Here, we performed SMD simulations to estimate 
the PMF profile of the 366–383 hairpin opening because we believe this motion is essential for the maturation of 
the enzyme. A harmonic time-dependent potential was added to the standard Hamiltonian of a collective variable 
controlling the phenomenon under investigation. In these calculations, the distance between the enzyme core 
(center of mass of the Cα atoms of Gln190, Arg194, and Arg237) and the center of mass of the Cα atoms of 
residues Ser373–Ser376 belonging to the 366–383 hairpin was used as descriptor. To avoid any protein distortions, 
the pulling velocity was set to 0.006 Å/ps, with a spring constant of 0.5 kcal/mol·Å2. The hairpin opening was 
simulated from 9.3 to 40.3 Å. The applied force and the external work performed on the system were calculated 
by applying the Amber scripts “ASMD.py” to determine which of the 50 replicas of the SMD simulations’ work 
values were the closest to the Jarzynski average. Additionally, “create.PMF.py” was used to depict the PMF 
profile. SMD simulations were conducted on the proPCSK9 model in which Gln152 and Ser153 were still bound. 
Umbrella sampling simulations. The energy barrier between the closed and supposedly open states of the 366–
383 hairpin was investigated by performing umbrella sampling (US) simulations using the pmemd.cuda tool of 
the Amber 2019 package.[24] The distance between the two mass centers used in the SMD simulations was chosen 
as a collective variable (CV). Ten windows of CV values from 9.15 to 22.00 Å were explored (Figure S1, 
Supporting Information), constraining the system to the specific CV values by harmonic constant ranging from 
1.5 to 2.5 kcal mol-1 Å-2. Each US window ran for 50 ns, reaching a total simulation time of 500 ns. The free energy 
profile was estimated by the weighted histogram analysis method, as implemented in the WHAM program 
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developed by Grossfield Laboratory.[27] The statistical uncertainty of the free energy profiles was estimated by 
Monte Carlo bootstrap error analysis. 
 
CpHMD simulations. CpHMD simulations[28] were conducted using the ff14SB Amber force field[29] to represent 
the protein atoms and the TIP3P model[30] to simulate the water environment. Titration curves were produced by 
performing 12 simulations at pH values from 0 to 12, for a total of 600-ns-long CpHMD simulations. During these, 
Asp186, His226 (both members of the catalytic triad), and the residues in their proximity (Asp224 and His229) 
were titrated. Moreover, to better characterize the protonation state of His226, 250-ns-long MD simulations were 
conducted at a constant pH of 7.2 in both the proPCSK9 and proPCSK9-cut models. The Amber script “cphstats” 
was used to parse the cpout files and to predict the residue protonation state and pKa values, creating files with 
the titration statistics for all simulations. For greater depth, “cphstats” were also used to compute the fraction of 
snapshots that the system spent in each state for each residue titrated during the simulations, resulting in a file 
named “populations.dat.”  
 
RESULTS AND DISCUSSION 
proPCSK9 models. To sample the conformational space of PCSK9 in the state preceding the second self-cleavage 
process, the proPCSK9 model—in which the prodomain was still bound to the PCSK9 catalytic and V domains 
(sequence 153–682)—was created by means of the Modeller algorithm (see Methods section).[22] The loops not 
solved by X-ray studies were properly sculpted inside the modeling procedure and, among 100 putative proPCSK9 
coarse models, the best model was optimized by 750-ns-long unbiased MD simulations. Strikingly, the obtained 
proPCSK9 model displayed an overall significant conformational stability, as explicated from the root mean square 
deviation (RMSD) plot (Figure S2, Supporting Information). Moreover, the visual inspection of the model 
revealed that the sequence shaping the P’ helix (residues 153–166) in the mature state (Figure 2A) was partially 
folded below the 366–383 hairpin. This conformation permitted the close contact of Gln152-Ser153 with the 
catalytic triad (Asp186, His226, and Ser386) responsible for the amide bond hydrolysis during the second self-
cleavage step. Moreover, the analysis of the Cα residue root mean square fluctuation (RMSF) plot (Figure 2B) 
evidenced that three proPCSK9 areas possessed the highest conformational flexibility: 1) the loop shaped by 
residues 169–178, 2) the 366–383 hairpin, and 3) the C-terminal domain. 
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Figure 2. A) Predicted conformation of the P’ helix in the proPCSK9 model (magenta) and in the X-ray structure 2P4E 
(green). The 366–383 hairpin is not shown for clarity. B) RMSF plot of the proPCSK9 Cα atoms during the unbiased MD 
simulations. 
   The conformational mobility of some PCSK9 areas observed on the RMSF plot can be rationalized considering 
that the 169–178 residues belong to an unsolved region of the X-ray (indicating an area endowed with a high 
conformational freedom)[18,31] and that the flexibility of the C-terminal domain does not greatly influence the 
catalytic domain activity since it is not in close contact with the residues involved in the serine-proteases activity 
of PCSK9. In contrast, the high conformational mobility shown by the 366–383 hairpin was unexpected. However, 
considering that it sizes the catalytic site, we suppose that its conformational freedom is needed to assist the P’ 
helix relocation subsequent to the auto-proteolysis process.  
   To validate this hypothesis, unbiased MD simulations were performed on a proPCSK9 model in which the 
Gln152-Ser153 peptide bond had just been cleaved (the proPCSK9-cut model). In these simulations, the 366–383 
hairpin conformational states were sampled, and the P’ helix relocation was determined. 
MD simulations on the proPCSK9-cut model. The 1-s-long MD simulation of the proPCSK9-cut model 
showed that despite the simulations starting from a conformation of Gln152-Ser153 (in which these residues were 
already close to each other during the minimization steps), the distance between the domain terms (Gln152-CO 
and Ser153-NH) increased to about 7 Å. Then, during 500-ns-long MD simulations, this distance progressively 
increased to the final crystallographic value of about 19 Å. Once this distance was reached, no further increases 
were observed during MD simulations (cyan line in Figure 3). Interestingly, these simulations revealed the P’ 
segment progressive folds as α-helix and the Ser153-NH relocation from the catalytic site by a slight opening of 
the 366–383 hairpin (orange line in Figure 3). In fact, as depicted in Figure 3, the His193Cα-Ser376Cα distance 
progressively increased together with the Gln152-Ser153 distance. Then, once Ser153 reached the optimal distance 
(Step 800 in Figure 3; about 19 Å), the 366–383 hairpin fluctuated at a value of 3 Å lower than the previous one. 
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Figure 3. The orange line depicts the 366–383 hairpin opening to allow the Ser153 relocation. The distance between the 
Ser376-Cα (in the center of the hairpin) and the His193-Cα (PCSK9 core) atoms was monitored during all steps of the 500-
ns-long MD simulations. The blue line shows the progressive removal of the Ser153 N-term from the catalytic site. 
 
 
However, the visual inspection of the MD trajectories permitted us to observe that the 366–383 hairpin opening is 
needed to allow the Ser153 N-term removal from the catalytic site. Consequently, to identify the presence of new 
366–383 hairpin conformations besides the one depicted in X-ray studies, the conformational states of the 366–
383 hairpin were sampled by SMD and US simulations. We hypothesize that an undescribed metastable 
conformational state of the enzyme could represent a target for structure-based drug design of a new generation of 
PCSK9 inhibitors. 
 
SMD and US simulations of the 366–383 hairpin. SMD simulations enable sampling of rare events as 
biomolecular conformational changes on time scales accessible to MD simulations. Here, we sampled the 366–
383 hairpin opening process, estimating the PMF of the system as a function of the distance between the hairpin 
and the PCSK9 core. This distance (see Methods for details) was progressively increased from the initial distance 
of 9.3 Å to 40.3 Å at a speed of 0.006 Å/ns. To acquire a satisfactory sampling, 50 SMD simulation replicas were 
run, and the Jarzynski equation[32] was applied to calculate the PMF associated with the hairpin opening 
progression (Figure 4).  
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Figure 4. A) Plot of the PMF versus the distance between the hairpin and the PCSK9 core. B) Representative conformations 
of the 366–383 hairpin. 
 
As shown in the PMF plot (Figure 4A), the presence of a saddle at the distance of 15–17 Å suggests that the 
hairpin could assume a metastable conformational state. In other words, the 366–383 hairpin spontaneously adopts 
the closed conformation, while a slightly open state could be shaped to allow for Ser153 N-term migration. 
Therefore, to evaluate the stability of the hairpin at the distance found in the saddle points, 500-ns-long unbiased 
MD simulations were performed on a trajectory frame showing the 366–383 hairpin at a distance of 16 Å from the 
enzyme core. Interestingly, these simulations displayed progressive hairpin closure, leading us to conclude that 
without any external bias (such as the one imposed by SMD), the hairpin assumed a stable closed conformation, 
as found in the mature (and crystallized) state of the enzyme. Consequently, the metastable conformational state 
identified on the PMF plot (Figure 4A) could represent only a transient hairpin conformation, allowing for the 
PCSK9 maturation (Figure 4B). 
Finally, it is well-known that the results of SMD depend on factors such as the pulling velocity or the value of k. 
Therefore, to verify the reliability of our findings, we also performed US calculations.[27,33] Consistent with the 
SMD outcomes, US simulations indicated that no stable hairpin open state conformation was identified (Figure 
5) since the barrier between the closed (distance 9 Å in Figure 5) and the open (distance 18 Å in Figure 5) state 




Figure 5. PMF obtained from US calculations using the hairpin distance from the enzyme core as the CV. 
 
    Nevertheless, another question remains unanswered in the maturation progression of PCSK9. Unlike other 
enzymes belonging to the same class as PCSK9, it is not clear why the protease activity of this enzyme does not 
proceed after the second maturation step. In other words, the reason why Gln152 is not cleaved from the prodomain 
during an additional (third) cleavage process remains undiscovered. We predicted that the answer to this question 
could be found by analyzing the protonation state of the catalytic triad (Asp186, His226, and Ser386) since the 
catalytic site, becoming accessible to the water environment after Ser153 relocation, could be strongly influenced 
by the presence of surrounding water molecules. To verify this hypothesis, CpHMD simulations were run. 
 
   CpHMD simulations. It is well-known that the protonation state of residues significantly affects the protein 
physiological functions. Experimental evidence of PCSK9 has confirmed this belief; in fact, PCSK9 shows five 
times greater affinity to LDLR at pH 5.5 than at pH 7.4.[18,20,34] Moreover, Ultsch et al.[36] recently proved that the 
31–60 sequence of PCSK9 displays a pH-sensitive folding. In this study, we conducted CpHMD to predict the 
protonation states of the titrable residues located in the catalytic site of PCSK9 residues. CpHMD simulations were 
performed at pH 7.2—the pH value of the endoplasmic reticulum in which PCSK9 undergoes the auto-maturation 
process—for both the proPCSK9 and proPCSK9-cut models. In particular, we focused on the protonation state of 
Asp186, His226 (both members of the catalytic triad), and some residues in their proximity (Asp224 and His229). 
Our simulations suggest that the majority of the inspected residues retained the expected/starting protonation state 
in both models. In particular, Asp186 and Asp224 were negatively charged, and His229 was monoprotonated. In 
contrast, it was interesting to note that only His226 changed its protonation state during the transition from the 
proPCSK9 to proPCSK9-cut models. It is well-known that histidine can exist in three equivalent tautomeric forms, 
distinguished into HID (Amber residues nomenclature, Figure 6A), when the hydrogen atom belongs to the 
imidazole -nitrogen atom; HIE, when the hydrogen is on the imidazole -nitrogen atom; and HIP in an acidic 
environment, in which both nitrogen atoms are protonated (Figure 6A). In the HIP state, the residue is positively 
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charged. The pKa value of the imidazole ring is 6.00, but depending on the protonation/solvation state of amino 
acids in the surrounding environment, this value can be dramatically different. Intriguingly, in our simulations of 
the proPCSK9 model, His226 exhibited the HID/HIE state for 92% of the simulation time and the HIP state for 
8% of the time. The calculated pKa was 6.14 (Figure 6B). In contrast, when CpHMD simulations were performed 
on the proPCSK9-cut model, His226 exhibited the HIP state for 97% of the simulation time and the HID state for 
the remaining time (less than 3%). In this case, a pKa of 8.7 was estimated (Figure 6B).  
   
 
Figure 6. A) Protonation state of histidine and Amber nomenclature. B) Titration curves of His226 from pH 0 to 12. 
Calculations were performed on the proPCSK9 model, in which Gln152 and Ser153 were still bound, and on the proPCSK9-
cut model, in which the amide bond joining both residues had just been hydrolyzed. C) Catalytic triad alignment before and 
after the Gln152-Ser153 hydrolysis. 
   Consequently, we can conclude that in the proPCSK9 state, His226 exists as an HID tautomer, allowing for the 
creation of an H-bond with the hydroxyl group of Ser386, while the hydrogen atom on the -nitrogen establishes 
an H-bond with the carboxylic group of Asp186 (Figure 6C). By this H-bond network, the catalytic triad is 
perfectly aligned, and the serine-protease activity of PCSK9 is fully active. Then, once the Ser153 is cleaved 
(simulations performed on the proPCSK9-cut model), the N-terminus relocation from the catalytic crevice exposes 
the catalytic triad to the water environment, leading to the variation in the protonation state of His226 from 
HID/HIE to HIP. In the conformational state in which PCSK9 is ready to bind to LDLR, His226 cannot create a 
stable H-bond with Ser386, the catalytic triad is not aligned, and consequently, PCSK9 cannot exert further serine-
protease activity. Moreover, in our simulations, it was observed that His226 created a salt bridge with the charged 
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Gln152 C-terminal end, contributing to the anchoring of the prodomain on the PCSK9 catalytic domain. The 
creation of this salt bridge, together with the changes in the protonation state of His226, explains why the PCSK9 
prodomain is protected from further self-hydrolysis reactions, contributing to making PCSK9 safe for other 
proteins present in the intracellular environment.  
To better understand the reasons for the shift in the pKa value of His226, we analyzed the simulation outputs with 
a focus on the microenvironment surrounding the catalytic triad, particularly the solvent accessibility of the single 
residue. For histidine residues, many studies have demonstrated the existence of a relationship between the pKa 
and its solvent accessibility, expressed as solvent accessible surface area (SASA).[37-39] The results of these 
investigations have shown that a higher solvent accessibility corresponds to a higher pKa of the basic residue. 
Consequently, we computed the average SASA of His226 on the proPCSK9 and proPCSK9-cut models by 
gmx_sasa script (implemented in the GROMACS package) using 100 frames extracted from the CpHMD 
simulations. The results indicated that the His226 SASA on the cleaved enzyme (proPCSK9-cut model) was 32 
Å2 higher than that of the zymogen proPCSK9. In fact, SASA values of 43.5 Å2 (mean err. = 2.3) and 11.3 Å2 
(mean err. = 1.6) were predicted for the proPCSK9-cut and proPCSK9 models, respectively. These data further 
confirm that in the cleaved enzyme, the His226 is more accessible to the solvent and therefore more prone to 
assume the HIP state. 
  Moreover, the spherical atomic radial distribution function g(r) was calculated between the nitrogen atoms of the 
His226 imidazole ring and the oxygen atoms of the solvent molecules over the MD trajectories of CpHMD 
simulations of both PCSK9 maturation states (Figure 7). The peaks in Figure 7 reveal how the density of water 
varies as a function of distance from the reference atoms (the nitrogen atoms of the His226 imidazole ring). The 
attained results highlight that the water density around His226 in the proPCSK9-cut model was double that 
predicted for proPCSK9, additionally confirming that the auto-catalytic cut of the enzyme exposes the catalytic 




Figure 7. Radial pair distribution function data for the proPCSK9 (orange line) and proPCSK9-cut (cyan line) models. The 
g(r) between the His226 side chain and the oxygen atoms of the solvent molecules was selected to acquire this plot. These 
data were attained by means of the VMD g(r) script.[41] 
 
CONCLUSIONS 
   PCSK9 plays a crucial role in the regulation of cholesterol homeostasis, constituting one of the most promising 
targets for the identification of drugs against hypercholesterolemia. For this reason, Xu et al.[5] described PCSK9 
as “a Holy Grail in the world of lowering LDL-C.” Until now, several inhibition strategies have been adopted to 
inhibit PCSK9, although the actual drugs in commerce are expensive mAbs. In this paper, we performed MD 
simulations (classical, SMD and US) to shed light on the PCSK9 maturation process with the goal of identifying 
new PCSK9 features that can be targeted by rational drug design. Starting from a complete PCSK9 model in the 
immature state (proPCSK9), we determined that PCSK9 conformational modification leads to the mature state of 
the enzyme, in which the P’ helix is shaped, and Gln152 and Ser153 are 20 Å apart. We speculate that the 
maturation process involves the putative opening of the 366–383 hairpin that, immediately after the Ser153-N-
term passage, returns to a closed conformation. This finding could open the way for the design of drugs capable 
of stabilizing the open state of the enzyme. In fact, a new generation of PCSK9 inhibitors capable of stabilizing 
the 366–383 hairpin in the open conformation could avoid the PCSK9/LDLR interaction, triggering the 
hypocholesterolemic effect. In this framework, the transient conformational state of proPCSK9 could be used as 
a target for the molecular docking of a virtual library of compounds (small molecules as well as small peptides). 
In these calculations, the centroid of the Ser153, Pro155, His229, and Ser225 residues should be the center of the 
box used for docking. 
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   Additionally, our findings suggests that His226 assumes the HIP state during molecular simulations of the mature 
state of the PCSK9. However, by CpHMD simulations, we predicted that His226 plays a key role in the catalytic 
activity of the enzyme. In fact, in the proPCSK9, His226 can assume the Nδ-protonated (HID) state, allowing for 
perfect alignment of the catalytic triad side chains. Then, in the mature state, the pKa of His226 was calculated 2 
units higher, leading to the hypothesis that His226 can adopt the double protonated (HIP) state. Thus, the 
explanation for why PCSK9 does not possess any serine-protease activity in the mature state is because it avoids 
the alignment of the catalytic triad. 
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By constant-pH MD simulations, the protonation state of the 
catalytic triad of PCSK9 was investigated. Moreover, the 
last step of the maturation process of the enzyme was 
figured out by MD simulations. This study paves the way to 
the design of ligands capable to interfere with the PCSK9 
maturation process. 
